Kelly et al. found heterogeneous expression of PD-L1 in MM patients and hypothesized that combination with a drug upregulating PD-L1 in tumor cells could potentiate the effect of PD-1/PD-L1 inhibition [17]. This evidence concerns the gene PDCD1 and Miyoshi myopathy.